

---

## HalioDx Signs an Agreement with Pronto Diagnostics to Make Immunoscore® Colon Assay Available in Israel

Marseille, France, July 31, 2018 – HalioDx SAS, an immuno-oncology diagnostic company, today announced that Pronto Diagnostics will market and distribute Immunoscore® Colon assay in Israel.

Oncologists and patients in Israel will have access to Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer. The assay guides oncologists to decide on critical therapeutic options in stage II and stage III colon cancers<sup>1</sup>. Immunoscore® Colon combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.

Immunoscore® Colon will be marketed in Israel by CTS Ltd, one of the leading Israeli pharma companies, through a joint cooperation between Pronto Diagnostics and CTS.

*“Colorectal cancer is the second most common malignant disease in Israel. According to the Israeli Ministry of Health most recent data in 2015 there were 3,016 new cases of Colorectal cancer of which ~ 2,228 are Colon cancer. We estimate that for approximately half of these cases the access to Immunoscore® Colon will enable physicians to assess better Colon cancer recurrence risk and adjust therapeutic options accordingly. We are excited to add Immunoscore® Colon to our portfolio of testing services in Israel and proud to introduce this important test to the Israeli market”, noted Nir Navot, CEO of Pronto Diagnostics.*

*“We are delighted to collaborate with Pronto Diagnostics, an expert company enabling Israeli oncologists and patients to access value-based diagnostic solutions,” added Vincent Fert CEO of HalioDx.*

Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study<sup>2</sup> conducted on more than 2600 patients have been published in [The Lancet journal](#). The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147<sup>3</sup> study.

---

<sup>1</sup> Hermitte J Immunother Cancer 2016

<sup>2</sup> Pagès et al. The Lancet 2018

<sup>3</sup> Sinicrope et al. Poster presentation ASCO GI 2018



Distributed by



Press release

---

## About Pronto Diagnostics

Pronto Diagnostics is a leader in molecular diagnostics in Israel, since its establishment in 1993. In its early days the company was one of the first companies globally to develop kits for mutation detection; over the years it has developed more than 35 CE IVD-marked kits for the diagnosis of mutations causing a variety of diseases.

Pronto Diagnostics is distributing products and unique devices from leading international manufacturers; it operates a molecular clinical diagnostic laboratory, accredited by the Israeli Ministry of Health, that is ISO 9001:2015 and ISO 27799 certified. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes.

Pronto represents in Israel some of the leading international service providers such as Centogene, Sequenom (part of Labcorp Inc), and more; it offers their tests in addition to its own services to Israeli institutional customers as well as to the private diagnostic market.

For more information, please visit [www.prontodiagnosics.com](http://www.prontodiagnosics.com)

## About HalioDx

### **The Immune Response to Cancer Diagnostics**

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

Two additional assays, Halioseek® & Immunosign®, have been developed by HalioDx and provide tools to help stratifying patients for immunotherapies.

HalioDx has an experienced team of more than 130 employees, a CLIA-certified laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites [www.halioldx.com](http://www.halioldx.com) and [www.immunoscore-colon.com](http://www.immunoscore-colon.com) and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).



Distributed by



Press release

---

## Contacts

### **HalioDx SAS**

#### **Vincent Fert**

President and CEO

+ 33 (0)4 91 29 30 90

[vincent.fert@haliodx.com](mailto:vincent.fert@haliodx.com)

### **ATCG Press**

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

[haliodx@atcg-partners.com](mailto:haliodx@atcg-partners.com)

[Twitter: twitter.com/haliodx](https://twitter.com/haliodx)